Search

Your search keyword '"Ray-Coquard, Isabelle"' showing total 2,286 results
Start Over Author "Ray-Coquard, Isabelle"
2,286 results on '"Ray-Coquard, Isabelle"'

151. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

Author

Oza, Amit M., Tinker, Anna V., Oaknin, Ana, Shapira-Frommer, Ronnie, McNeish, Iain A., Swisher, Elizabeth M., Ray-Coquard, Isabelle, Bell-McGuinn, Katherine, Coleman, Robert L., O'Malley, David M., Leary, Alexandra, Chen, Lee-may, Provencher, Diane, Ma, Ling, Brenton, James D., Konecny, Gottfried E., Castro, Cesar M., Giordano, Heidi, Maloney, Lara, Goble, Sandra, Lin, Kevin K., Sun, James, Raponi, Mitch, Rolfe, Lindsey, and Kristeleit, Rebecca S.

Published
2017
Full Text
View/download PDF

152. Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

Author

Trédan, Olivier, primary, Toulmonde, Maud, additional, Le Tourneau, Christophe, additional, Montane, Laure, additional, Italiano, Antoine, additional, Ray-Coquard, Isabelle, additional, De La Fouchardière, Christelle, additional, Bertucci, François, additional, Gonçalves, Anthony, additional, Gomez-Roca, Carlos, additional, You, Benoit, additional, Attignon, Valéry, additional, Boyault, Sandrine, additional, Cassier, Philippe A., additional, Dufresne, Armelle, additional, Tabone-Eglinger, Séverine, additional, Viari, Alain, additional, Sohier, Emilie, additional, Kamal, Maud, additional, Garin, Gwenaël, additional, Blay, Jean-Yves, additional, and Pérol, David, additional

Published
2023
Full Text
View/download PDF

153. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation

Author

Willing, Eva-Maria, primary, Vollbrecht, Claudia, additional, Vössing, Christine, additional, Weist, Peggy, additional, Schallenberg, Simon, additional, Herbst, Johanna M., additional, Schatz, Stefanie, additional, Jóri, Balázs, additional, Bataillon, Guillaume, additional, Harter, Philipp, additional, Salutari, Vanda, additional, Martin, Antonio Gonzáles, additional, Vergote, Ignace, additional, Colombo, Nicoletta, additional, Roeper, Julia, additional, Berg, Tobias, additional, Berger, Regina, additional, Kah, Bettina, additional, Noettrup, Trine Jakobi, additional, Falk, Markus, additional, Arndt, Kathrin, additional, Polten, Andreas, additional, Ray-Coquard, Isabelle, additional, Selzam, Franziska, additional, Pirngruber, Judith, additional, Schmidt, Stefanie, additional, Hummel, Michael, additional, Tiemann, Markus, additional, Horst, David, additional, Sehouli, Jalid, additional, Pujade-Lauraine, Eric, additional, Tiemann, Katharina, additional, Braicu, Elena Ioana, additional, and Heukamp, Lukas C., additional

Published
2023
Full Text
View/download PDF

154. TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.

Author

Janjigian, Yelena Y., primary, Oaknin, Ana, additional, Lang, Joshua Michael, additional, Ciombor, Kristen Keon, additional, Ray-Coquard, Isabelle Laure, additional, Oza, Amit M., additional, Yonemori, Kan, additional, Xu, Rui-Hua, additional, Zhao, Jimmy, additional, Gajavelli, Srikanth, additional, Filant, Justyna, additional, Hovey, Tina, additional, and Meric-Bernstam, Funda, additional

Published
2023
Full Text
View/download PDF

155. PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients

Author

Gauduchon, Thibault, primary, Kfoury, Maria, additional, Lorusso, Domenica, additional, Floquet, Anne, additional, Ventriglia, Jole, additional, Salaun, Hélène, additional, Moubarak, Malak, additional, Rivoirard, Romain, additional, Polastro, Laura, additional, Favier, Laure, additional, You, Benoit, additional, Berton, Dominique, additional, de la Motte Rouge, Thibault, additional, Mansi, Laura, additional, Abdeddaim, Cyril, additional, Prulhiere, Karine, additional, Lancry Lecomte, Laurence, additional, Provansal, Magali, additional, Dalban, Cécile, additional, and Ray-Coquard, Isabelle, additional

Published
2023
Full Text
View/download PDF

157. Blinded-assessment of a solution to evaluate olaparib maintenance treatment efficacy in patients with ovarian cancer from the GINECO/ENGOT PAOLA-1 trial.

Author

Buisson, Adrien, primary, Saintigny, Pierre, additional, Constantoulakis, Pantelis, additional, Oikonomaki, Katerina, additional, Samara, Stavroula, additional, Harter, Philipp, additional, Pignata, Sandro, additional, Gonzalez Martin, Antonio, additional, Schauer, Christian, additional, Fujiwara, Keiichi, additional, Vergote, Ignace, additional, Colombo, Nicoletta, additional, Pujade-Lauraine, Eric, additional, Treilleux, Isabelle, additional, and Ray-Coquard, Isabelle Laure, additional

Published
2023
Full Text
View/download PDF

158. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775

Author

Makker, Vicky, primary, Colombo, Nicoletta, additional, Herráez, Antonio Casado, additional, Monk, Bradley J., additional, Mackay, Helen, additional, Santin, Alessandro D., additional, Miller, David S., additional, Moore, Richard G., additional, Baron-Hay, Sally, additional, Ray-Coquard, Isabelle, additional, Ushijima, Kimio, additional, Yonemori, Kan, additional, Kim, Yong Man, additional, Guerra Alia, Eva M., additional, Sanli, Ulus A., additional, Bird, Steven, additional, Orlowski, Robert, additional, McKenzie, Jodi, additional, Okpara, Chinyere, additional, Barresi, Gianmaria, additional, and Lorusso, Domenica, additional

Published
2023
Full Text
View/download PDF

159. Figure S8 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

160. Supplementary Table 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

161. FIGURE 3 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

162. FIGURE 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

163. FIGURE 4 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

164. FIGURE 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

165. Data from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

166. Supplementary Table 2 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

167. Supplementary Table 1 from Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, primary, Pommier, Roxane M., primary, Treilleux, Isabelle, primary, Boyault, Sandrine, primary, Devouassoux-Shisheboran, Mojgan, primary, Kielbassa, Janice, primary, Thomas, Emilie, primary, Tonon, Laurie, primary, Le Texier, Vincent, primary, Charreton, Amandine, primary, Morel, Anne-Pierre, primary, Floquet, Anne, primary, Joly, Florence, primary, Berton-Rigaud, Dominique, primary, Ferron, Gwenaël, primary, Arnould, Laurent, primary, Croce, Sabrina, primary, Bataillon, Guillaume, primary, Saintigny, Pierre, primary, Mery-Lamarche, Eliane, primary, Sagan, Christine, primary, Senaratne, Aruni P., primary, Gut, Ivo G., primary, Calvo, Fabien, primary, Viari, Alain, primary, Ouzounova, Maria, primary, Ray-Coquard, Isabelle, primary, and Puisieux, Alain, primary

Published
2023
Full Text
View/download PDF

168. Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy

Author

Lequesne, Justine, primary, Joly, Florence, additional, Peron, Julien, additional, Ray-Coquard, Isabelle, additional, Hardy-Bessard, Anne-Claire, additional, Selle, Frédéric, additional, Berton, Dominique, additional, Follana, Philippe, additional, Fabbro, Michel, additional, Lortholary, Alain, additional, Pujade-Lauraine, Eric, additional, Lefèvre-Arbogast, Sophie, additional, and Coquan, Elodie, additional

Published
2023
Full Text
View/download PDF

169. Corrigendum to ‘Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study’ [Eur J Cancer 171 (2022) 183–192]

Author

Conforti, Fabio, primary, Gronchi, Alessandro, additional, Penel, Nicholas, additional, Jones, Robin L., additional, Broto, Javier M., additional, Sala, Isabella, additional, Bagnardi, Vincenzo, additional, Napolitano, Andrea, additional, Pala, Laura, additional, Pennacchioli, Elisabetta, additional, Catania, Chiara, additional, Queirolo, Paola, additional, Grigani, Giovanni, additional, Merlini, Alessandra, additional, Stacchiotti, Silvia, additional, Comandone, Alessandro, additional, Vincenzi, Bruno, additional, Quagliuolo, Vittorio, additional, Bertuzzi, Alexia, additional, Boglione, Antonella, additional, Palassini, Elena, additional, Baldi, Giacomo G., additional, Blay, Jean-Yves, additional, Ryckewaert, Thomas, additional, Toulmonde, Maud, additional, Italiano, Antoine, additional, Le Cesne, Axel, additional, Ray-Coquard, Isabelle, additional, Cruz, Josefina, additional, Hernández-León, Carmen N., additional, Trufero, Javier M., additional, da Silva Moura, David, additional, Muñiz, Nadia H., additional, and De Pas, Tommaso, additional

Published
2023
Full Text
View/download PDF

171. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group

Author

Penel, Nicolas, Le Cesne, Axel, Bonvalot, Sylvie, Giraud, Antoine, Bompas, Emmanuelle, Rios, Maria, Salas, Sébastien, Isambert, Nicolas, Boudou-Rouquette, Pascaline, Honore, Charles, Italiano, Antoine, Ray-Coquard, Isabelle, Piperno-Neumann, Sophie, Gouin, François, Bertucci, François, Ryckewaert, Thomas, Kurtz, Jean-Emmanuel, Ducimetiere, Françoise, Coindre, Jean-Michel, and Blay, Jean-Yves

Published
2017
Full Text
View/download PDF

175. Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

Author

Patrikidou, Anna, Chaigneau, Loic, Isambert, Nicolas, Kitikidou, Kyriaki, Shanley, Ryan, Ray-Coquard, Isabelle, Valentin, Thibaud, Malivoir, Bettina, Laigre, Maryline, Bay, Jacques-Olivier, Moureau-Zabotto, Laurence, Bompas, Emmanuelle, Piperno-Neumann, Sophie, Penel, Nicolas, Alcindor, Thierry, Guillemet, Cécile, Duffaud, Florence, Hügli, Anne, Le Pechoux, Cécile, Dhermain, Frédéric, Blay, Jean-Yves, Sperduto, Paul W., and Le Cesne, Axel

Published
2020
Full Text
View/download PDF

176. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial

Author

González-Martín, Antonio, Desauw, Christophe, Heitz, Florian, Cropet, Claire, Gargiulo, Piera, Berger, Regina, Ochi, Hiroyuki, Vergote, Ignace, Colombo, Nicoletta, Mirza, Mansoor R, Tazi, Youssef, Canzler, Ulrich, Zamagni, Claudio, Guerra-Alia, Eva M, Levaché, Charles B, Marmé, Frederik, Bazan, Fernando, de Gregorio, Nikolaus, Dohollou, Nadine, Fasching, Peter A, Scambia, Giovanni, Rubio-Pérez, María J, Milenkova, Tsveta, Costan, Cristina, Pautier, Patricia, Ray-Coquard, Isabelle, PAOLA1/ENGOT-ov25 investigators, Gonzalez-Martin, A, Desauw, C, Heitz, F, Cropet, C, Gargiulo, P, Berger, R, Ochi, H, Vergote, I, Colombo, N, Mirza, M, Tazi, Y, Canzler, U, Zamagni, C, Guerra-Alia, E, Levache, C, Marme, F, Bazan, F, de Gregorio, N, Dohollou, N, Fasching, P, Scambia, G, Rubio-Perez, M, Milenkova, T, Costan, C, Pautier, P, and Ray-Coquard, I

Subjects
Ovarian Neoplasms, Cancer Research, Science & Technology, Antineoplastic Agents, Carcinoma, Ovarian Epithelial, Poly(ADP-ribose) Polymerase Inhibitors, Piperazines, Progression-Free Survival, Bevacizumab, Settore MED/40 - GINECOLOGIA E OSTETRICIA, PARP inhibitor, Olaparib, Antiangiogenic agent, Second progression-free survival, Double-Blind Method, Oncology, Ovarian cancer, Antineoplastic Combined Chemotherapy Protocols, Humans, Phthalazines, Female, Life Sciences & Biomedicine
Abstract

BACKGROUND: PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab versus placebo plus bevacizumab in newly diagnosed, advanced ovarian cancer. We report the prespecified main second progression-free survival (PFS2) analysis for PAOLA-1. METHODS: This randomised, double-blind, phase III trial was conducted in 11 countries. Eligible patients had newly diagnosed, advanced, high-grade ovarian cancer and were in response after first-line platinum-based chemotherapy plus bevacizumab. Patients were randomised 2:1 to olaparib (300 mg twice daily) or placebo for up to 24 months; all patients received bevacizumab (15 mg/kg every 3 weeks) for up to 15 months. Primary PFS end-point was reported previously. Time from randomisation to second disease progression or death was a key secondary end-point included in the hierarchical-testing procedure. RESULTS: After a median follow-up of 35.5 months and 36.5 months, respectively, median PFS2 was 36.5 months (olaparib plus bevacizumab) and 32.6 months (placebo plus bevacizumab), hazard ratio 0.78; 95% confidence interval (CI) 0.64-0.95; P = 0.0125. Median time to second subsequent therapy or death was 38.2 months (olaparib plus bevacizumab) and 31.5 months (placebo plus bevacizumab), hazard ratio 0.78; 95% CI 0.64-0.95; P = 0.0115. Seventy-two (27%) patients in the placebo plus bevacizumab group received a poly(ADP-ribose) polymerase inhibitor as first subsequent therapy. No new safety signals were observed for olaparib plus bevacizumab. CONCLUSION: In newly diagnosed, advanced ovarian cancer, maintenance olaparib plus bevacizumab provided continued benefit beyond first progression, with a significant PFS2 improvement and a time to second subsequent therapy or death delay versus placebo plus bevacizumab. ispartof: EUROPEAN JOURNAL OF CANCER vol:174 pages:221-231 ispartof: location:England status: published

Published
2022

177. HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial.

Author

Fabbro, Michel, Lamy, Pierre-Jean, Touraine, Célia, Floquet, Anne, Ray-Coquard, Isabelle, and Mollevi, Caroline

Subjects
CLINICAL trials, PROGRESSION-free survival, PROGNOSIS, OVARIAN epithelial cancer, MULTIVARIATE analysis, MEDICAL screening, OVARIAN cancer
Abstract

HE4 and CA-125 are used for epithelial ovarian cancer (EOC) screening, diagnosis, and follow-up. Our objective was to study HE4 and CA-125 kinetics in patients treated for recurrent EOC. Serum samples were prospectively collected before the first chemotherapy cycle and every 3 months until disease progression. Data from 89/101 patients could be analyzed. At baseline, the median CA-125 and HE4 concentrations were 210 IU/L (7-10,310) and 184 pM (31-4,836). Among the 12 patients (13%) with normal CA-125 (<35 IU/L) concentration, eight had HE4 concentration ≥75 pM, and among the 16 patients with normal HE4 concentration (18%), 12 had increased CA-125 concentration. The median nadir concentrations were 31 IU/L (3-8,744) for CA-125 and 75 pM (20-4,836) for HE4. The median times to nadir were 14 (0-130) weeks for CA- 125 and 12 (0-52) weeks for HE4. In multivariate analysis, CA-125 and HE4 nadir concentrations (<35 IU/L, HR 0.35, 95% CI: 0.17-0.72 and<75 pM, HR 0.40, 95% CI: 0.20-0.79) and time to CA-125 and HE4 nadir (>14 weeks, HR 0.37, 95% CI: 0.20-0.70 and >12 weeks, HR 0.43, 95% CI: 0.23-0.83) were prognostic factors of progression-free survival. More investigations on HE4 kinetics could help to better monitor patients with CA-125 concentration within normal values. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

178. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.

Author

Neyrand, Sophie, Trecourt, Alexis, Lopez, Jonathan, Just, Pierre Alexandre, Descotes, Françoise, Borson‐Chazot, Françoise, Ray‐Coquard, Isabelle, Decaussin‐Petrucci, Myriam, and Devouassoux‐Shisheboran, Mojgan

Subjects
GENES, RNA sequencing, GENETIC mutation, DNA sequencing, THYROID cancer, BRAF genes, OVARIAN follicle, THYROID gland
Abstract

Aims: Struma ovarii (SO) are rare, accounting for 0.3–1% of ovarian tumours, and include benign and malignant lesions. In most cases, histology is not predictive of clinical outcome and prognosis. The prognosis of histologically malignant thyroid‐type carcinomas can indeed be excellent, while SO, composed of normal thyroid tissue, can recur and are designated highly differentiated follicular carcinoma of the ovary. Clearer diagnostic criteria are therefore required. Methods and results: We retrospectively studied 31 SO using DNA and RNA sequencing with pan‐cancer gene panels, including eight biologically malignant SO (BMSO) defined based on ovarian serosal or extra‐ovarian dissemination at presentation or during follow‐up, 10 stage IA histologically malignant SO (HMSO) with thyroid‐type carcinoma morphology and 13 biologically and histologically benign SO (BSO), with none of the above‐mentioned characteristics. Molecular alterations were observed in 87.5% of BMSO, 70% of HMSO and 7.7% of BSO (P < 0.001). All patients with a peritoneal dissemination at presentation or during follow‐up had at least one gene alteration. BRAF mutations (44.5%) were only observed in malignant forms (HMSO and BMSO) and TERT promoter alterations (25%) only in cases of BMSO. The BRAF p.G469A mutation, which is extremely rare in thyroid carcinomas, was the molecular alteration most frequently associated with malignant SO (28.5%). Conclusion: Our results highlight the clinical utility of molecular sequencing in SO, based on this limited number of cases. However, as malignant SO evolve slowly, more extensive molecular studies in SO with more than 10 years' follow‐up are required to draw any conclusions on the prognostic value of the associated gene alterations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

179. Management of Rare Uterine Malignant Tumors

Author

Amant, Frederic, primary, Hensley, Martee, additional, Pautier, Patricia, additional, Friedlander, Michael, additional, Sagae, Satoru, additional, Fujiwara, Keiichi, additional, Berton Rigaud, Dominique, additional, Lorusso, Domenica, additional, and Ray-Coquard, Isabelle, additional

Published
2019
Full Text
View/download PDF

183. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety

Author

Kristeleit, Rebecca S, Oaknin, Ana, Ray-Coquard, Isabelle, Leary, Alexandra, Balmaña, Judith, Drew, Yvette, Oza, Amit M, Shapira-Frommer, Ronnie, Domchek, Susan M, Cameron, Terri, Maloney, Lara, Goble, Sandra, Lorusso, Domenica, Ledermann, Jonathan A, and McNeish, Iain A

Published
2019
Full Text
View/download PDF

185. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

Author

Mir, Olivier, Brodowicz, Thomas, Italiano, Antoine, Wallet, Jennifer, Blay, Jean-Yves, Bertucci, François, Chevreau, Christine, Piperno-Neumann, Sophie, Bompas, Emmanuelle, Salas, Sébastien, Perrin, Christophe, Delcambre, Corinne, Liegl-Atzwanger, Bernadette, Toulmonde, Maud, Dumont, Sarah, Ray-Coquard, Isabelle, Clisant, Stéphanie, Taieb, Sophie, Guillemet, Cécile, Rios, Maria, Collard, Olivier, Bozec, Laurence, Cupissol, Didier, Saada-Bouzid, Esma, Lemaignan, Christine, Eisterer, Wolfgang, Isambert, Nicolas, Chaigneau, Loïc, Cesne, Axel Le, and Penel, Nicolas

Published
2016
Full Text
View/download PDF

187. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration

Author

Small, Mathilde, Treilleux, Isabelle, Couillault, Coline, Pissaloux, Daniel, Picard, Géraldine, Paindavoine, Sandrine, Attignon, Valery, Wang, Qing, Rogemond, Véronique, Lay, Stéphanie, Ray-Coquard, Isabelle, Pfisterer, Jacobus, Joly, Florence, Du Bois, Andreas, Psimaras, Dimitri, Bendriss-Vermare, Nathalie, Caux, Christophe, Dubois, Bertrand, Honnorat, Jérôme, and Desestret, Virginie

Published
2018
Full Text
View/download PDF

188. Dissecting the origin of heterogeneity in uterine and ovarian carcinosarcomas

Author

Sertier, Anne-Sophie, primary, Ferrari, Anthony, additional, Pommier, Roxane M., additional, Treilleux, Isabelle, additional, Boyault, Sandrine, additional, Devouassoux-Shisheboran, Mojgan, additional, Kielbassa, Janice, additional, Thomas, Emilie, additional, Tonon, Laurie, additional, Le Texier, Vincent, additional, Charreton, Amandine, additional, Morel, Anne-Pierre, additional, Floquet, Anne, additional, Joly, Florence, additional, Berton-Rigaud, Dominique, additional, Ferron, Gwenaël, additional, Arnould, Laurent, additional, Croce, Sabrina, additional, Bataillon, Guillaume, additional, Saintigny, Pierre, additional, Mery-Lamarche, Eliane, additional, Sagan, Christine, additional, Senaratne, Aruni P., additional, Gut, Ivo G., additional, Calvo, Fabien, additional, Viari, Alain, additional, Ouzounova, Maria, additional, Ray-Coquard, Isabelle, additional, and Puisieux, Alain, additional

Published
2023
Full Text
View/download PDF

189. CREB fusion–associated epithelioid mesenchymal neoplasms of the female adnexa: three cases documenting a novel location of an emerging entity and further highlighting an ambiguous misleading immunophenotype

Author

Trecourt, Alexis, primary, Macagno, Nicolas, additional, Ngo, Carine, additional, Philip, Charles-André, additional, Lopez, Jonathan, additional, Ferreira, Joana, additional, Alves-Vale, Catarina, additional, Ray-Coquard, Isabelle, additional, Genestie, Catherine, additional, Agaimy, Abbas, additional, and Devouassoux-Shisheboran, Mojgan, additional

Published
2023
Full Text
View/download PDF

190. Abstract CT058: TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors

Author

Meric-Bernstam, Funda, primary, Janjigian, Yelena, additional, Lang, Joshua, additional, Ciombor, Kristen K., additional, Ray-Coquard, Isabelle, additional, Oza, Amit, additional, Yonemori, Kan, additional, Xu, Ruihua, additional, Zhao, Jimmy L., additional, Gajavelli, Srikanth, additional, Filant, Justyna, additional, Hovey, Tina, additional, and Oaknin, Ana, additional

Published
2023
Full Text
View/download PDF

191. Table S2 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Author

Lin, Kevin K., primary, Harrell, Maria I., primary, Oza, Amit M., primary, Oaknin, Ana, primary, Ray-Coquard, Isabelle, primary, Tinker, Anna V., primary, Helman, Elena, primary, Radke, Marc R., primary, Say, Carmen, primary, Vo, Lan-Thanh, primary, Mann, Elaina, primary, Isaacson, Jeffrey D., primary, Maloney, Lara, primary, O'Malley, David M., primary, Chambers, Setsuko K., primary, Kaufmann, Scott H., primary, Scott, Clare L., primary, Konecny, Gottfried E., primary, Coleman, Robert L., primary, Sun, James X., primary, Giordano, Heidi, primary, Brenton, James D., primary, Harding, Thomas C., primary, McNeish, Iain A., primary, and Swisher, Elizabeth M., primary

Published
2023
Full Text
View/download PDF

192. Figures S1-S8 from BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Author

Lin, Kevin K., primary, Harrell, Maria I., primary, Oza, Amit M., primary, Oaknin, Ana, primary, Ray-Coquard, Isabelle, primary, Tinker, Anna V., primary, Helman, Elena, primary, Radke, Marc R., primary, Say, Carmen, primary, Vo, Lan-Thanh, primary, Mann, Elaina, primary, Isaacson, Jeffrey D., primary, Maloney, Lara, primary, O'Malley, David M., primary, Chambers, Setsuko K., primary, Kaufmann, Scott H., primary, Scott, Clare L., primary, Konecny, Gottfried E., primary, Coleman, Robert L., primary, Sun, James X., primary, Giordano, Heidi, primary, Brenton, James D., primary, Harding, Thomas C., primary, McNeish, Iain A., primary, and Swisher, Elizabeth M., primary

Published
2023
Full Text
View/download PDF

193. Sarcomes utérins du stroma de haut grade et sarcomes indifférenciés – Référentiels de prise en charge du Groupe Sarcome Français et du groupe des Tumeurs Rares Gynécologiques

Author

Roussel-Simonin, Cyril, primary, Croce, Sabrina, additional, Guyon, Frédéric, additional, Llacer, Carmen, additional, Ray-Coquard, Isabelle, additional, Meeus, Pierre, additional, Genestie, Catherine, additional, Taieb, Sophie, additional, Malhaire, Caroline, additional, Duffaud, Florence, additional, and Pautier, Patricia, additional

Published
2023
Full Text
View/download PDF

194. Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study

Author

Mery, Benoîte, primary, Ménétrier-Caux, Christine, additional, Montané, Laure, additional, Heudel, Pierre-Etienne, additional, Ray-Coquard, Isabelle, additional, Bachelot, Thomas, additional, Derbel, Olfa, additional, Augereau, Paule, additional, Treilleux, Isabelle, additional, Berthet, Justine, additional, Nkodia, Axelle, additional, Bardin-Dit-Courageot, Christine, additional, Attignon, Valery, additional, Ferrari, Anthony, additional, Garin, Gwenaele, additional, Perol, David, additional, Caux, Christophe, additional, Dubois, Bertrand, additional, and Trédan, Olivier, additional

Published
2023
Full Text
View/download PDF

195. Avancées thérapeutiques dans la prise en charge des tumeurs rares malignes ovariennes

Author

Lebreton, Coriolan, primary, Quesada, Stanislas, additional, Bini, Marta, additional, Babin, Guillaume, additional, Rossi, Léa, additional, Chopin, Nicolas, additional, Croce, Sabrina, additional, Hartog, Cécile, additional, Renaud, Tiphaine, additional, Gaillard, Anne-Lise, additional, Petit, Adeline, additional, Serre, Anne-Agathe, additional, Trédan, Olivier, additional, Rowinski, Elise, additional, Cockenpot, Vincent, additional, Treilleux, Isabelle, additional, Rousset-Jablonski, Christine, additional, Méeus, Pierre, additional, Guyon, Frédéric, additional, and Ray-Coquard, Isabelle, additional

Published
2023
Full Text
View/download PDF

196. Comparison between exclusive (chemo)radiation and surgery or induction chemotherapy as first curative treatment for localized or locally advanced head and neck squamous cell carcinomas (L(A)-HNSCC): Sub-analysis of the EPOCKS study

Author

Gauduchon, Coauthor(s) Thibault, primary, Dalban, Cécile, additional, Philippe, Zrounba, additional, Racadot, Séverine, additional, Chabaud, Sylvie, additional, Reyt, Emile, additional, Poupart, Marc, additional, Prades, Jean Michel, additional, Burgy, Michael, additional, Cellier, Dominique, additional, Ceruse, Philippe, additional, Leval, Jacques, additional, Muller, Philippe, additional, Manipoud, Patrick, additional, Ray-Coquard, Isabelle, additional, and Fayette, Jérôme, additional

Published
2023
Full Text
View/download PDF

197. Data from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Author

Toulmonde, Maud, primary, Brahmi, Mehdi, primary, Giraud, Antoine, primary, Chakiba, Camille, primary, Bessede, Alban, primary, Kind, Michèle, primary, Toulza, Emilie, primary, Pulido, Marina, primary, Albert, Sabrina, primary, Guégan, Jean-Philippe, primary, Cousin, Sophie, primary, Mathoulin-Pelissier, Simone, primary, Perret, Raul, primary, Croce, Sabrina, primary, Blay, Jean-Yves, primary, Ray-Coquard, Isabelle, primary, Floquet, Anne, primary, and Italiano, Antoine, primary

Published
2023
Full Text
View/download PDF

198. Supplementary Figure from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Author

Toulmonde, Maud, primary, Brahmi, Mehdi, primary, Giraud, Antoine, primary, Chakiba, Camille, primary, Bessede, Alban, primary, Kind, Michèle, primary, Toulza, Emilie, primary, Pulido, Marina, primary, Albert, Sabrina, primary, Guégan, Jean-Philippe, primary, Cousin, Sophie, primary, Mathoulin-Pelissier, Simone, primary, Perret, Raul, primary, Croce, Sabrina, primary, Blay, Jean-Yves, primary, Ray-Coquard, Isabelle, primary, Floquet, Anne, primary, and Italiano, Antoine, primary

Published
2023
Full Text
View/download PDF

199. Supplementary Figure 9 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author

You, Benoit, primary, Robelin, Patrick, primary, Tod, Michel, primary, Louvet, Christophe, primary, Lotz, Jean-Pierre, primary, Abadie-Lacourtoisie, Sophie, primary, Fabbro, Michel, primary, Desauw, Christophe, primary, Bonichon-Lamichhane, Nathalie, primary, Kurtz, Jean-Emmanuel, primary, Follana, Philippe, primary, Leheurteur, Marianne, primary, Piano, Francesco Del, primary, Ferron, Gwénael, primary, De Rauglaudre, Gaëtan, primary, Ray-Coquard, Isabelle, primary, Combe, Pierre, primary, Chevalier-Place, Annick, primary, Joly, Florence, primary, Leary, Alexandra, primary, Pujade-Lauraine, Eric, primary, Freyer, Gilles, primary, and Colomban, Olivier, primary

Published
2023
Full Text
View/download PDF

200. Supplementary Table from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Author

Toulmonde, Maud, primary, Brahmi, Mehdi, primary, Giraud, Antoine, primary, Chakiba, Camille, primary, Bessede, Alban, primary, Kind, Michèle, primary, Toulza, Emilie, primary, Pulido, Marina, primary, Albert, Sabrina, primary, Guégan, Jean-Philippe, primary, Cousin, Sophie, primary, Mathoulin-Pelissier, Simone, primary, Perret, Raul, primary, Croce, Sabrina, primary, Blay, Jean-Yves, primary, Ray-Coquard, Isabelle, primary, Floquet, Anne, primary, and Italiano, Antoine, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results